Pacira Biosciences authorizes $300M share repurchase program through Dec 31, 2026

Pacira BioSciences, Inc.

Board approved $300M stock buyback, effective immediately, replacing the May 7, 2024 program.
Repurchases may be made on open market or via privately negotiated transactions at management's discretion.
Program expires December 31, 2026; can be suspended or discontinued at any time by the company.
No obligation to repurchase any specific number of shares under the authorization.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.